Investigational drug · Phase 2
ABS-1230
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for KCNT1-Related Epilepsy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ABS-1230"
First trial start
2026
May 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABS-1230", any sponsor or status.
Conditions studied
As listed on its trial records.
- KCNT1-Related Epilepsy
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABS-1230" as an intervention, largest first.
Actio Biosciences, Inc.Industry
NCT07156201 · 92 participants (planned) · Start Aug 28, 2025 · Primary completion Dec 2026
Drug: ABS-1230; Placebo and 2 more · For: KCNT1-Related Epilepsy
Sites: Sydney, Australia
Actio Biosciences, Inc.Industry
NCT07600736 · 61 participants (planned) · Start May 18, 2026 · Primary completion Jan 2027
Drug: ABS-1230; Placebo · For: KCNT1-Related Epilepsy
Sites: Hackensack, New Jersey; Rochester, New York
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.